A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://ncbi.nlm.nih.gov/pubmed/24373380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-613
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky